MedDay Secures €34 Million ($38.5M) New Funding

Biotin is an emerging therapy for the treatment of secondary progressive MS.

MedDay Secures €34 Million ($38.5M) New Funding

Postby ton » Fri Apr 08, 2016 9:58 am

Please visit this web:
User avatar
Family Member
Posts: 74
Joined: Thu May 27, 2010 3:00 pm


Re: MedDay Secures €34 Million ($38.5M) New Funding

Postby CureOrBust » Fri Apr 08, 2016 4:34 pm

A direct link: ... w-funding/

Friday, April 08, 2016
MedDay Secures €34 Million ($38.5M) New Funding
Edmond de Rothschild Investment Partners led the Series B financing alongside existing investors Sofinnova Partners and InnoBio. Large Venture also participated in the operation.

Funds will drive a confirmatory phase 3 study in US to treat progressive multiple sclerosis with MedDay’s wholly-owned lead candidate, MD1003

Does anyone know if the following statement only relates to people who were in the original studies? or is there a method to access the MD100 (as opposed to sourcing your own Biotin)?
The drug is already commercialized in some European countries under “named patient use”.
User avatar
Family Elder
Posts: 3348
Joined: Wed Jul 27, 2005 3:00 pm
Location: Sydney, Australia

Return to Biotin (Qizenday, Cerenday, MD1003)


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service